MOTS-c: the peptide your own mitochondria writes

MOTS-c: el péptido que tu propia mitocondria escribe

There's a detail of your biology that still surprises the scientists who found it.

Inside almost every one of your cells there are tiny structures called mitochondria. They're the power plants: they turn what you eat into usable fuel. You knew that part.

What was discovered in 2015 is that mitochondria also write. They carry their own DNA, separate from the DNA in the nucleus, and inside that DNA are instructions for making a very small hormone that travels into the bloodstream and talks to the rest of the body.

That hormone is called MOTS-c. And what it does is one of the more elegant things in modern physiology.

Educational content. Not medical advice. Results vary.

What MOTS-c is, in plain words

The name is an ugly but literal acronym: Mitochondrial Open reading frame of the Twelve S rRNA-c. Translated: "the little stretch of code inside the 12S gene of mitochondrial DNA."

It's 16 amino acids long. Tiny. For reference, insulin has 51.

For decades, mitochondrial DNA was assumed to do exactly one job: build the parts of the energy machinery. Nothing else. A spare-parts manual.

MOTS-c changed that. It showed there are also instructions for sending signals in there — that mitochondria aren't just a quiet factory, but something that reports back to the rest of the body on how energy is going.

Think of it this way: your city's power plant doesn't only generate electricity. It also sends word when demand spikes. MOTS-c is that word.

The gene nobody was reading

In 2015, a team at the Leonard Davis School of Gerontology at the University of Southern California published the finding in Cell Metabolism, one of the serious journals in the field.

They went looking on purpose. Another mitochondrial peptide called humanin was already known, so they asked a reasonable question: if there's one, are there more? They read through mitochondrial DNA hunting for short stretches of code capable of producing peptides that nobody had catalogued.

They found MOTS-c. Then they described what it does:

• Its main target organ appears to be skeletal muscle — the muscle you move on purpose.
• Inside the cell it interferes with a chemical pathway called the folate cycle.
• That causes a molecule called AICAR to build up.
• And AICAR switches on an enzyme called AMPK.

The lever: what AMPK is

If you keep one name from this whole article, keep this one.

AMPK is your cell's energy sensor. When a cell runs short on fuel, AMPK switches on and gives three very specific orders: burn fat, pull in glucose, stop storing.

What else switches AMPK on naturally? Exercise. Fasting. Cold. Metformin.

Meaning: MOTS-c isn't some exotic molecule doing something strange. It pulls exactly the same lever as the things we already know improve metabolism. That's why the field got excited about it, and the excitement is reasonable.

What the research showed

In that same 2015 paper, the team injected MOTS-c into mice. Two results, both solid:

One. Mice fed a high-fat diet — the standard way to fatten a lab mouse — didn't gain the same weight if they received MOTS-c.

Two. The treatment prevented insulin resistance: both the kind that comes with age and the kind a diet causes.

Other teams followed the thread. In 2019, a study in Physiological Reports analyzed the blood of obese mice treated with MOTS-c and found three metabolic pathways that run hot in obesity and type 2 diabetes came down.

And in 2021, work in Biochimica et Biophysica Acta showed something worth underlining: MOTS-c and exercise amplify each other. Treadmill training raised MOTS-c in muscle, along with AMPK and PGC-1α — the protein that orders new mitochondria to be built. They don't compete; they add up.

What's been measured in people

This is the part that has grown most in recent years, and it's the most useful part for you.

Your MOTS-c rises when you train

A Karolinska Institute study measured mitochondrial-derived peptides in people before and after acute exercise. Endurance exercise (45 minutes of cycling) raised circulating mitochondrial peptides; MOTS-c trended upward. Acute resistance training, in that protocol, did not.

And there's a curious recent finding: in active men, repeated heat exposure significantly raised circulating MOTS-c. Heat, like exercise, appears to speak to the mitochondria.

And when it rises, it doesn't rise alone

This is the finding we like most, because it connects the number to real life.

A randomized trial of 16 weeks of aerobic and resistance exercise in breast cancer survivors measured MOTS-c before and after. In the group that trained, MOTS-c rose significantly compared with usual care.

And that rise didn't come alone. Post-exercise levels were associated with:

• less fat mass
• less body weight
• more lean mass
• better HOMA-IR (the insulin resistance index)
• lower CRP (C-reactive protein, an inflammation marker)

The study also found the response varies by ethnic group, possibly through mitochondrial DNA variants. In that work, Hispanic survivors started from a worse metabolic profile and didn't show the same rise. It's an honest reminder that this biology isn't identical for everyone — and one more reason to have someone look at your particular case.

Low levels say something too

In women with polycystic ovary syndrome, a 2026 study in Scientific Reports found less than half the blood MOTS-c of controls matched for age and weight: 220 pg/mL versus 498. Also less in muscle, measured by biopsy.

And in people with type 2 diabetes and revascularized coronary disease, MOTS-c below 167 ng/mL predicted worse two-year cardiovascular outcomes, independently of other factors.

Summing up the human picture: more MOTS-c travels with a metabolism that's working; less MOTS-c travels with a metabolism in trouble. That's measured, in people, and it repeats across different populations.

Where the research stands today

Now the part we'd rather tell you ourselves before you find it somewhere else.

Everything you just read about people comes from observational and exercise studies: they measure the MOTS-c your body already makes and see what it tracks with.

What isn't published yet is the next step: a trial that administers MOTS-c to one group and placebo to another, then measures who lost weight and whose insulin improved.

That doesn't mean it doesn't work. The biology is real, the mechanism is the right one, and the human signal points the expected direction. It means something more precise: the mechanism and the association are demonstrated; the outcome piece is still on its way.

We'd rather you knew that from the start. If someone promises you an exact number of pounds from this peptide, they're handing you an answer science hasn't given yet — and that says more about the seller than about the product.

How it's used properly — and why that changes everything

For us, this is the most important distinction in the whole article.

Most MOTS-c sold online carries a label: for research use only. That phrase isn't a minor legal technicality. It means the product was not made to go into a human body.

In practice, with that vial:

• Nobody verifies purity. There's no independent analysis guaranteeing the label matches the contents.
• Nobody verifies the dose. The real content can be far above or far below what's stated.
• Nobody verifies sterility. And we're talking about something injectable.
• There's nobody to hold accountable. If something goes wrong, the seller reminds you it said "research use only."

A product prepared by a licensed pharmacy, under a prescription from a physician who reviewed your case, is a completely different category. Same peptide, different worlds: chain of custody, controlled dose, sterility, a responsible professional and someone to call.

If you're going to use MOTS-c, that's the only version that makes sense. And it's exactly how we offer it.

What the U.S. rules actually say

Let's be precise, because there's a lot of confused information circulating on this.

MOTS-c is not an FDA-approved drug. There's no approved label and no official indication. That has to be said plainly.

What does exist is the compounding pharmacy route. In the United States, a licensed pharmacy can prepare a customized medication under prescription using bulk substances. The FDA maintains a list for this — the 503A Bulks List — and also runs an interim policy for substances that are nominated and under review, so treatment isn't interrupted while the process moves.

MOTS-c is dispensed today through that route: by prescription, through licensed pharmacies, while the FDA completes its evaluation.

That process is underway right now. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee met in Silver Spring, Maryland to evaluate several peptides. MOTS-c was one, alongside BPC-157, TB-500, KPV, Semax and Epitalon. The uses the FDA evaluated for MOTS-c are in the public agenda: obesity and osteoporosis.

The committee is advisory and its recommendations are non-binding. No final decision has been published.

If you compete in any sport, read this

Short and serious, and we include it because we'd rather you weren't caught out.

MOTS-c is prohibited at all times by the World Anti-Doping Agency, under metabolic modulators, precisely because it's an AMPK activator. "At all times" means in and out of competition.

If you compete in any organized sport — from a college team to a masters league — this can cost you a sanction. It isn't a question of dose or intent.

Worth noting in passing: that an anti-doping agency bothers to ban something means they consider it capable of changing performance. That isn't proof of efficacy, but it isn't a meaningless detail either.

What this evidence does NOT say

We always include this section. It's what makes the rest worth trusting.

It does NOT say how much weight you'll lose. That number hasn't been measured in a human trial. Nobody can give it to you honestly.

It does NOT say it replaces exercise. It shares a lever with exercise. Exercise also does many things no injection does: heart, bone, sleep, mood, balance at 75.

It does NOT say raising your level artificially reproduces what was seen when training raised it. That's the reasonable hypothesis, and it's exactly what's left to demonstrate.

It does NOT say the FDA approved it. An advisory committee reviewed it. That's a different thing, and the difference matters.

It does NOT say it works the same for everyone. The breast cancer survivor study found different responses across ethnic groups. That's why it's assessed case by case.

Who is this NOT for?

• Athletes in organized competition. A sanction is close to guaranteed if you're tested.
• Pregnancy and breastfeeding. No data. Not the moment to experiment.
• Active cancer or a recent history of it. Signals that touch cell metabolism and the folate cycle need your oncologist in the conversation.
• Diabetes on medication, without supervision. If you're already on metformin or insulin, you're pulling the same pathway from two directions. That's done with a physician watching, not on your own.
• Under 18. No.
• Anyone looking to skip the basics. If the idea is to inject this instead of fixing sleep, food and movement, the peptide isn't the problem — and it won't be the solution either.

Frequently asked questions

Can I get it from a compounding pharmacy?

Yes. It's prepared by a licensed pharmacy, under prescription, after a physician reviews your case. It is not an FDA-approved drug and it is not on the final 503A Bulks List: it's dispensed under the FDA's interim policy while its review continues.

How long before I notice anything?

There's no timeline established in human trials, so we won't invent one. What we do know is that in the exercise studies, changes in MOTS-c and in the metabolic profile were measured at 16 weeks. That's a horizon of months, not days.

Is it the same as semaglutide or tirzepatide?

No, and it's worth being clear. GLP-1s have randomized trials with tens of thousands of people and FDA approval. MOTS-c has a solid mechanism, animal data and human associations. Those are two different levels of evidence, and they belong to two different conversations with your physician.

Can I combine it with exercise?

That's exactly what the research suggests. In mice, MOTS-c and training amplify each other through the same pathway (AMPK and PGC-1α). And in people, the higher levels showed up precisely in those who trained. Everything points to this accompanying movement, not replacing it.

Does exercise alone raise my MOTS-c?

Partly yes: endurance exercise raises it, and 16 weeks of aerobic and resistance training raised it significantly in a randomized trial. A study using eight weeks of moderate exercise found no change, so it likely depends on type, intensity and the person.

Is it banned in sport?

Yes. The World Anti-Doping Agency prohibits it at all times, in and out of competition, as a metabolic modulator because it's an AMPK activator.

How we offer it

We wrote this article with one goal: that by the time you reached this section you'd already have the full picture — the good and what's missing — and could decide for yourself.

Yes, we do offer MOTS-c. And the way we offer it matters more to us than the product itself.

Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. Depending on your medical history and where you are, a clinician may schedule a video appointment with you if they determine it's required.

From there:

• Prescription required. It's Rx. Not a supplement, not a vial from a website.
• Licensed pharmacy. They prepare your order, with their chain of custody and their controls.
• Direct shipping to your door, in two days.
• Care team available for your questions — you're not left alone with a box.
• Recurring deliveries and dosage personalization through an optional monthly check-in.
• Cancel any time, in one click.

The injectable MOTS-c program is available from $225/month, on a two-months-on, one-month-off schedule. And if reviewing your case suggests a different route makes more sense for you, we'll say so: we also offer clinically supervised weight management and hormone health programs, and GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149/month, by telemedicine, in Spanish and English.

Eligibility is determined by medical evaluation. Individual results vary and are not guaranteed.

Sources

Articles located through PubMed.

• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. 10.1016/j.cmet.2015.02.009
• Dieli-Conwright CM, Sami N, Norris MK, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Sci Rep. 2021;11(1):16916. 10.1038/s41598-021-96419-z
• von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol. 2021;131(3):1035-1042. 10.1152/japplphysiol.00706.2019
• Elhusseiny R, Ihsan M, Labidi M, et al. Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Med Sci Sports Exerc. 2025;57(12):2764-2774. 10.1249/MSS.0000000000003825
• Kutuk IS, Akin S, Demirel H, et al. Reduced serum and skeletal muscle MOTS-c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction. Sci Rep. 2026;16(1). 10.1038/s41598-026-39687-x
• Ikonomidis I, Katogiannis K, Kyriakou E, et al. β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. J Thromb Thrombolysis. 2020;49(3):365-376. 10.1007/s11239-020-02060-4
• Yang B, Yu Q, Chang B, et al. MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2021;1867(6):166126. 10.1016/j.bbadis.2021.166126
• Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. 10.14814/phy2.14171
• U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
• U.S. Anti-Doping Agency. What is the MOTS-c peptide? usada.org

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medications. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform, and preparations are dispensed by licensed pharmacies. Eligibility is determined by a licensed provider. MOTS-c is not FDA-approved for any use and is not on the final 503A Bulks List; it is dispensed by prescription under the FDA's interim policy while its review continues. It is prohibited in competitive sport. Any treatment decision belongs to a licensed physician who evaluates your case. Individual results vary and are not guaranteed.